Taysha Gene Therapies shares tumble following pricing shares at $6.00
· seekingalpha.com
Taysha Gene Therapies (TSHA) shares slumped 9.2% after-hours on Wednesday after pricing of an underwritten public offering of its common stock and pre-funded warrants, aiming to bring in approximately $200M in gross proceeds before underwriting discounts
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...